GET DAILY SIGNALSWhy Is ADMA Biologics (ADMA) Stock Down -0.83% Today?
Key Takeaways
- Exact move: ADMA shares were down about 0.83% to $13.10 in Friday afternoon trading, versus a prior-session close of $13.21.
- Primary driver: Profit-taking and consolidation after Thursday's roughly 26% earnings-driven surge, the stock's strongest single-session gain of the year.
- Secondary factor: A disclosed Rule 10b5-1 insider sale by CEO Adam Grossman, along with technical resistance just above current levels.
- Broader context: The pullback follows a Q3 beat on revenue, earnings, and margins, led by 31% growth in the ASCENIV product franchise.
- What traders are watching next: Whether the stock holds above its 200-day moving average near $10.85 and whether it can clear the roughly $13.80 resistance zone.
- Get more details on Price Targets, Earnings, and Forecast for this ticker on dedicated pages.
- Explore Trending AI Robots to see the top-performing automated trading strategies for this and thousands of other tickers.
Opening Summary
ADMA Biologics, Inc. (ADMA) is a Ramsey, New Jersey-based biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived immune globulin therapies for immune deficiencies and infectious diseases, led by its flagship products ASCENIV and BIVIGAM. In Friday's session, the stock eased about 0.83% to $13.10, down from Thursday's close of $13.21. The modest decline reflects profit-taking and consolidation a day after the shares spiked roughly 26% on better-than-expected third-quarter results, rather than any fresh negative fundamental news.
Post-Earnings Consolidation and Profit-Taking
The primary reason ADMA shares slipped Friday is straightforward: after a roughly 26% single-day surge, some investors locked in gains. Thursday's rally lifted the stock from $10.48 to $13.21, and a portion of that move is being given back as short-term traders and momentum participants book profits. This type of consolidation is common after a large gap-and-rally session and does not, by itself, signal a change in the underlying bullish catalyst that drove the advance.
The Earnings Catalyst Behind the Rally
The pullback comes on the heels of a powerful earnings-driven move. For the third quarter, ADMA reported revenue of $141.1 million, up about 5% year over year and above the roughly $138 million consensus estimate, while adjusted earnings of $0.23 per share beat the approximately $0.20 per share forecast. GAAP net income rose 37% to $49.9 million, and gross margin expanded sharply to 71% from 56% a year earlier. Growth was powered by ASCENIV, whose revenue climbed 31% year over year to $124.7 million, even as the older BIVIGAM product saw softer demand. Management also reiterated full-year 2026 revenue guidance of at least $530 million and raised its adjusted EBITDA outlook.
Insider Activity and Technical Resistance
Two secondary factors contributed to the subdued tone. First, a regulatory filing showed CEO Adam Grossman sold 147,000 shares for roughly $1.76 million on Thursday under a pre-arranged Rule 10b5-1 trading plan, a routine disclosure that can nevertheless weigh on sentiment. Second, the stock now sits just below a technical resistance zone near $13.80, the 50% retracement of its 2026 trading range. After Thursday's gap higher reclaimed both the 50-day and 200-day moving averages in a single session, the shares are pausing at this level as the market digests the strength of the recovery.
Market Context and Trading Activity
Thursday's surge occurred on volume of about 8.5 million shares, roughly triple the stock's average daily volume, confirming strong conviction behind the earnings re-rating. Friday's lighter, drift-lower action suggests the post-earnings buying wave has cooled. The move is largely idiosyncratic to ADMA rather than a broad biotechnology-sector signal, as the rally was driven by company-specific results and guidance rather than macro or index-level momentum. Traders are watching whether the stock can hold its reclaimed 200-day moving average near $10.85 on any pullback while attempting to clear resistance near $13.80.
What Comes Next for ADMA
Looking ahead, investors will monitor whether ASCENIV's utilization momentum carries into the fourth quarter and whether BIVIGAM demand stabilizes as management has indicated. Key watch items include the trajectory of accounts receivable, which management noted rose above its target range during the quarter, and the company's high customer concentration, with a small number of customers accounting for a large share of revenue. The stock also continues to carry overhang from an earlier short-seller report and related shareholder litigation, though the strong results and expanded margins undercut some of those claims. Risks include competitive pricing pressure in the immune globulin market and any slowdown in new patient starts. The company's next quarterly report will be a critical test of whether the earnings re-rating can be sustained.
Trending AI Robots
Tickeron offers hundreds of AI-driven trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are highlighted in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a way to track automated signals across diverse market environments. Explore Trending AI Robots to see which automated strategies are currently leading the pack.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ADMA's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for ADMA moved out of overbought territory on November 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In 30 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
ADMA broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on ADMA as a result. In 74 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on November 05, 2026. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +5.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in 245 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 210 of 254 cases where ADMA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.985) is normal, around the industry mean (3.498). P/E Ratio (17.681) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.170) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology